Eli Lilly and Kowa Pharma debut new statin Livalo in USA
US drug major Eli Lilly and partner Kowa Pharmaceuticals America (a subsidiary of Japan's Kowa) have this week launched their new cholesterol lowerer Livalo (pitavastatin) through retail pharmacists in the USA.
Livalo was approved by the US Food and Drug Administration in August 2009 for the treatment of adults as an adjunctive therapy to diet for primary hyperlipidemia or mixed dyslipidemia. It is the subject of a co-promotion accord - which includes Latin America 'signed by the two companies last year, financial terms of which were not disclosed. The drug is available in doses of 1mg, 2mg and 4mg.
Livalo, approved on the basis of 10 clinical trials, including five 12-week clinical trials comparing efficacy and safety to three currently FDA-approved statins (atorvastatin, simvastatin, and pravastatin), offered low-density lipoprotein cholesterol (LDL-C) lowering of up to 39% at a 2mg dose and up to 45% at a 4mg dose.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze